Breaking News, Financial News

Financial Report: Evotec 3Q

Revenues decline in the quarter, up 8% YTD

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec 3Q Revenues: €22.2 million (-16%) 3Q Earnings: €5.9 million (-30%) YTD Revenues: €64.2 million (+8%) YTD Earnings: €7.5 million (-18%) Comments: YTD growth was driven by an increase in revenues from the company’s drug discovery alliances, Andromeda/Teva, Boehringer Ingelheim (€2.5 million) and Novartis, and revenues from upfront payments from the CureBeta partnership with Janssen and contributions from acquisitions of Evotec Munich and Evotec San Francisco....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters